Atypical Hemolytic-Uremic Syndrome: Clinical manifestations and challenges in diagnosis

• Autor(a) principal: Mota, Lennara Pereira
• Data de Publicação: 2021
• Outros Autores: Sousa, Maria Vitalina Alves de, Penha, Ana Alinne Gomes da, Cardoso, Alexandra Rodrigues, Sousa, Francisco de Assis da Silva, Freitas, Francilene Vieira da Silva, Dantas, Josana de Mello, Costa, Thaline Ravena Nunes, Silva, Thaynara Alves Rodrigues Paulo da, Silveira Filho, Eudes Rufino da, Rosário, Wilian Reis, Silva, Regina Célia da, Gois, Lucas Costa de, Costa, Jaqueline Dantas da, Carvalho, Mayara Madeira de, Pereira, Stefânia Araújo, Santos, Joice Mara Ferreira dos
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Research, Society and Development
• Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/18365
• topic: Microangiopatias; Anemia Hemolítica; Síndrome Urêmica; Diagnóstico.; Microangiopatías; Anemia hemolítica; Síndrome urémico; Diagnóstico.; Microangiopathies; Hemolytic anemia; Uremic Syndrome; Diagnosis.

Atypical hemolytic uremic syndrome (aHUS) is characterized by a triad of thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure. The pathogenesis of HUS corresponds to thrombotic microangiopathy (THA). The work aims to expose through the analysis of scientific articles the main clinical manifestations and challenges in the diagnosis of Atypical Hemolytic-Uremic Syndrome. This is a literature review of a qualitative nature based on scientific production based on studies published between 2018 and 2021. Although atypical hemolytic uremic syndrome is rare, it is related to complications and important sequelae secondary to alterations of kidney function; 42% of children and 27% of adults may have severe thrombocytopenia (<50,000 platelets/mL). Similarly, related acute kidney injury is severe in 59% of children and 81% of adults, and may be accompanied by glomerular involvement, creatinine, hematuria, proteinuria, edema, and hypertension. The treatment that is most effective against aHUS is the use of the drug Eculizumab. This drug has a high cost, but studies show an increase in life expectancy and quality of life for these patients with the use of this medication. It is necessary that more studies about this disease are carried out for the development of new diagnostic measures and therapies against aHUS at a lower cost and with easy access for the population due to the seriousness of the disease and its high mortality rate.